Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development

Objective

With an aging population and >55 million dementia cases worldwide; treatments are more needed than ever. However, effective treatments are lacking, with solutions only stalling dementia progress and no real disease-modifying effect. ATI has developed AT-001, a new drug with the potential to stop and revert the disease, and to delay its onset. AT-001 has been developed through the DNACA precision-medicine based platform, which applies Big Data mining and Deep Learning/AI algorithms to identify patients with validated biomarkers. AT-001 is different in that it prevents aggregation of amyloid/tau proteins, common in many types of dementia. Phase IIa clinical trials have shown strong effects in the treatment of HCCAA. We will now carry out a registration trial for commercialization in Iceland and POC studies in Europe to obtain NDA in familial dementia, thereby informing the treatment of Alzheimer’s Disease (60% of dementia cases), potentially changing the lives of millions for the better.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

ARCTIC THERAPEUTICS EHF
Net EU contribution
€ 2 500 000,00
Address
BREKKUBAER 24
110 Reykjavik
Iceland
SME
Yes
Region
Ísland Ísland Höfuðborgarsvæði
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 571 875,00